Virus Research Institute

Avant Immunotherapeutics, Inc.

Therion Biologics Corporation

Lendon G Payne

Alexander K Andrianov

Sharon A Jenkins

Bryan E Roberts

Sameer S Sule

Jonathan R Sargent

Yichen Lu

Angela L Woods

A soluble polyphosphazene polyelectrolyte immunoadjuvant is disclosed. In one embodiment, the polymeric adjuvant is poly&lsqb;di(carboxylatrophenoxy)phosphazene&rsqb; which is in the form of a microsphere and which is adsorbed with antigen after formation of the microsphere. The immunoadjuvant can be administered intranasally.

Polyphosphazene microspheres

A polyphosphazene polyelectrolyte immunoadjuvant having improved water solubility, a vaccine composition of the immunoadjuvant and an antigen or immunogen and methods of their use in producing or enhancing an immunoprotective response in a host are disclosed.

Polyphosphazene polyelectrolyte immunoadjuvants

A composition and method for inducing a protective immune response to HIV-1 in an individual, of (a) a replication incompetent HIV-1, HIV-1 pseudovirus, HIV-1 VLP or oligomeric gp120; and (b) a water soluble polyphosphazene polyelectrolyte, wherein (a) and (b) are present in an amount effective to induce a protective immune response against HIV-1.

HIV-1 prophylactic composition and method

The invention pertains to self-assembled replication defective hybrid virus-like particles having capsid and membrane glycoproteins from at least two different virus types and method of making same. Recombinant viral vectors as well as the viral particles can be used as immunogens and drug delivery vehicles.

Self-assembling replication defective hybrid virus particles

Water soluble polymers or polymeric hydrogels are used to encapsulate antigen to form vaccines. The antigen is mixed with a polymer solution, microparticles are formed of the polymer and antigen, and, optionally, the polymer is crosslinked to form a stable microparticle. Preferred polymers are alginate and polyphosphazenes, and mixtures thereof. Microparticles can be adminstered parenterally or mucosally. For oral delivery, the microparticles are preferably fifteen microns or less in diameter, and adhere to the mucosal lining of the gastrointestinal tract, increasing uptake by the reticuloendothelium.

Hydrogel microencapsulated vaccines

An immunoadjuvant soluble polyphosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer.

Growing community of inventors

Arlington, MA, United States of America

Lendon G Payne